Clinical Microbiology & Infection

Living with ESBLs
pp. 1-2(2)
Authors: Cornaglia, G.; Garau, J.; Livermore, D. M.

Defining an extended-spectrum β-lactamase
pp. 3-10(8)
Author: Livermore, D. M.

Evolution of extended-spectrum β-lactamases by mutation
pp. 11-32(22)
Author: Gniadkowski, M.

The spread of CTX-M-type extended-spectrum β-lactamases
pp. 33-41(9)
Authors: Rossolini, G. M.; D'Andrea, M. M.; Mugnaioli, C.

Minor extended-spectrum β-lactamases
pp. 42-52(11)
Authors: Naas, T.; Poirel, L.; Nordmann, P.

IRT and CMT β-lactamases and inhibitor resistance
pp. 53-62(10)
Authors: Cantón, R.; Morosini, M. I.; Martin, O.; de la Maza, S.; de la Pedrosa, E. Gomez G.

Extended-spectrum β-lactamases: structure and kinetic mechanism
pp. 63-74(12)
Author: Page, M. G. P.

Genetic support of extended-spectrum β-lactamases
pp. 75-81(7)
Authors: Poirel, L.; Naas, T.; Nordmann, P.

Extended-spectrum β-lactamases and the permeability barrier
pp. 82-89(8)
Authors: Martínez-Martínez, L.

Phenotypic detection of extended-spectrum β-lactamase production in Enterobacteriaceae: review and bench guide
pp. 90-103(14)
Authors: Drieux, L.; Brossier, F.; Sougakoff, W.; Jarlier, V.

Extended-spectrum β-lactamases in ambulatory care: a clinical perspective
pp. 104-110(7)
Authors: Rodríguez-Baño, J.; Navarro, M. D.

Extended-spectrum β-lactamases in long-term-care facilities
pp. 111-116(6)
Authors: Nicolas-Chanoine, Marie-Hélène; Jarlier, Vincent

Animal reservoirs for extended spectrum β-lactamase producers
pp. 117-123(7)
Author: Carattoli, A.

Control of infections due to extended-spectrum β-lactamase-producing organisms in hospitals and the community
pp. 124-133(10)
Authors: Warren, R. E.; Harvey, G.; Carr, R.; Ward, D.; Doroshenko, A.

Extended-spectrum β-lactamases in North America, 1987-2006
pp. 134-143(10)
Author: Bush, K.

Prevalence and spread of extended-spectrum β-lactamase-producing Enterobacteriaceae in Europe
pp. 144-153(10)
Authors: Cantón, R.; Novais, A.; Valverde, A.; Machado, E.; Peixe, L.; Baquero, F.; Coque, T. M.

Prevalence of extended-spectrum β-lactamases in South America
pp. 154-158(5)
Authors: Villegas, M. V.; Kattan, J. N.; Quinteros, M. G.; Casellas, J. M.

Prevalence and clonality of extended-spectrum β-lactamases in Asia
pp. 159-165(7)
Author: Hawkey, P. M.

Breakpoints for extended-spectrum β-lactamase-producing Enterobacteriacae: pharmacokinetic/pharmacodynamic considerations
pp. 166-168(3)
Author: MacGowan, A.

Breakpoints for intravenously used cephalosporins in Enterobacteriaceae—EUCAST and CLSI breakpoints
pp. 169-174(6)
Author: Kahlmeter, G.

Parenteral carbapenems
pp. 175-180(6)
Author: Shah, P. M.

Antibiotic policy and prescribing strategies for therapy of extended-spectrum β-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam
pp. 181-184(4)
Author: Peterson, L. R.

Sulbactam-containing β-lactamase inhibitor combinations
pp. 185-188(4)
Author: Akova, M.

Orthodox and unorthodox clavulanate combinations against extended-spectrum β-lactamase producers
pp. 189-193(5)
Authors: Livermore, D. M.; Hope, R.; Mushtaq, S.; Warner, M.

β-Lactams without a suicide inhibitor
pp. 194-197(4)
Author: Giamarellou, H.

Other antimicrobials of interest in the era of extended-spectrum β-lactamases: fosfomycin, nitrofurantoin and tigecycline
pp. 198-202(5)
Author: Garau, J.